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.2012.01.0Abstract In Malaysia, therapeutic drug monitoring (TDM) service was started in the 1980s. Since
then, the number of hospitals that offer the service has increased. In this paper, we report the ﬁnd-
ings of a nationwide survey describing the practice of TDM in these hospitals. Questionnaires were
mailed to 128 government hospitals. Data were collected for general characteristics of the hospitals,
administrative, and laboratory activities related to TDM service. One hundred and twenty-one hos-
pitals responded to the survey. Thirty-four hospitals (28.1%) provided the service with their own
TDM laboratories, 44 hospitals (36.4%) provided the service using other hospitals’ laboratories
and 43 hospitals (35.5%) did not provide the service at all. TDM services were more likely to be
offered in larger hospitals with various medical specialties. Since it is managed entirely by hospital
pharmacists, these pharmacists assume an important role in ensuring optimum use of the TDM ser-
vice.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Therapeutic drug monitoring (TDM) is a useful clinical tool in
drug therapy. Nationwide surveys of TDM service in other
countries have been reported (Murphy et al., 1996; Morris,
1998; Thomson et al., 1998; Pedersen et al., 2000). In Malaysia,
TDM service was ﬁrst provided by the Hospital Universiti67 1191; fax: +60 9 767 1199.
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02Sains Malaysia (HUSM) in 1984 (Hassan, 1993). Later, other
hospitals in the country started to provide this service as part
of drug monitoring service to their patients (Matnor, 1996;
Othman et al., 1996). In 1987, four hospitals provided the
TDM service and the number of hospitals with the service in-
creased steadily to 73 in 2005 (Ministry of Health, 1988, 1992,
2002, 2005). Gentamicin was the ﬁrst drug to be monitored
when the service was ﬁrst introduced (Hassan, 1990; Ismail,
1990). Since then, the service has been expanded to include
antiepileptic drugs, digoxin and theophylline.
The total number of cases monitored by TDM services for
the whole country increased from 25,756 in 1998 to 61,907 in
2005 an increase of 140.4% within seven years (Ministry of
Health, 1988, 1992, 2002, 2005). In this survey, we have
attempted to determine the current practice of TDM amongier B.V. All rights reserved.
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ity of clinical and analytical components of the service.
2. Methods
A cross sectional study design was used to obtain information
on TDM from the hospitals in Malaysia. The questionnaire
was developed based on various studies, surveys and review
articles on TDM service from different countries like the
USA, UK and Australia (Murphy et al., 1996; Morris, 1998;
Crawford and Santell, 1994; Howard et al., 1994; Morris and
Lam, 2002; Perez et al., 2006).
The target hospitals were all government hospitals inMalay-
sia. Addresses and telephone numbers of the hospitals were ob-
tained from the website of the Ministry of Health, Malaysia
(Ministry of Health, 2006). A self-addressed stamped envelope
together with the questionnaire was mailed to the targeted hos-
pitals. The questionnaire was written in English language with a
covering letter that explained the aim of the study. The cover
letter and a questionnaire were addressed to the chief pharma-
cist of each hospital. The ﬁrst mailing of the questionnaire was
in May 2006. The ﬁrst reminder with a copy of the question-
naire was mailed two months later in July 2006. The second re-
minder was done one month later to non-responding hospitals
by phone calls between September and October 2006.
The questionnaire sought to identify the following informa-
tion: general and demographic information, TDM service
operational hours, drugs monitored, number and source of
samples, and reporting procedures. In addition, the question-
naire asked about physicians’ acceptance toward the pharma-
cist therapeutic recommendations. A section of the
questionnaire was dedicated to laboratory activities, which
asked about the location of the TDM laboratory in the hospi-
tal, and type of assay technique used. This section also asked
about the availability of a quality assurance (QA) program
in the laboratory. The draft survey was reviewed and evaluated
by two pharmacists with extensive experience in TDM service
in Malaysia. The questionnaire was pretested in March 2006 at
three hospitals with TDM services. It consisted of multiple-
choice and open-ended questions.
Data were analyzed using the Statistical Package for Social
Sciences (SPSS) program (Ver. 12.0). Descriptive statistics
with frequencies, mean ± SD, median and range were used
where appropriate. Percentages were calculated based on the
number of respondents who answered each particular ques-
tion. Mann–Whitney test was used due to skewed data to eval-
uate differences in the availability of TDM service based on
hospital characteristics. An a priori P value of less than 0.05
was considered statistically signiﬁcant.
3. Results
One hundred and twenty-three (96.1%) respondents returned
the questionnaires. Two questionnaires were excluded (one
was returned unﬁlled and the other stated that the hospital
did not have inpatient service). Seventy-eight (64.5%) respon-
dents reported providing TDM services at their hospitals.
Thirty-four hospitals provided TDM services and performed
their own drug assays. Forty-four hospitals provided the ser-
vices but the drug concentration measurements were done in
other hospitals. For these respondents, data are presented based
on the number of respondents who answered each particularquestion in the survey. Forty-three hospitals did not provide
the service at all and did not answer the remaining questions.
Hospitals that provided TDM service had signiﬁcantly lar-
ger number of beds, higher number of clinical specialties, and
higher number of pharmacists employed (Mann–Whitney test,
P< 0.001). A similar trend was observed when comparing
hospitals that had their own drug assay facilities with hospitals
that did not have their own drug assay facilities (Table 1). The
duration of providing TDM service ranged from less than a
year to 22 years. Most respondents reported providing the ser-
vice ﬁve days a week. In hospitals with drug assay facilities, 20
(58.8%) respondents said they provided the service during the
normal working hours (8 h/day) and with an ‘‘on-call’’ phar-
macist after the normal working hours. During ‘‘on-call’’ ser-
vice, a pharmacist will be paged or called by the hospital
when a TDM request is received. Two (5.9%) respondents said
their hospitals provided 24-h service. One respondent from the
hospital without drug assay facility said it provided an ‘‘on-
call’’ service as well as during the normal working hours.
There was a wide variation in the types of drugs monitored
by TDM services in these hospitals (Table 2). Aminoglycosides
and antiepileptic drugs like phenytoin, carbamazepine and so-
dium valproate, were among the most commonly monitored
drugs in these hospitals. On average, hospitals with their
own drug assay facilities provided monitoring to about 10 dif-
ferent drugs whereas hospitals without the assay facilities mon-
itored about ﬁve different types of drug only. The average
number of blood samples received by hospitals with drug assay
facilities was higher than that received by hospitals without the
facilities. Respondents from hospitals with drug assay facilities
also reported receiving blood samples from external sources
(Table 3). In addition, 90.9% of these respondents said that
the number of samples received had been increasing over the
years. Fifty percent of the respondents in hospitals without as-
say facilities reported a similar trend.
When asked how the assay results were communicated to
the doctors, the majority of respondents said that they gave
their pharmacokinetic consultations and dosing recommenda-
tions to doctors by phone (84.4%) or using a TDM request
form (88.9%). Four respondents from the hospital with drug
assay facilities said they used the hospital’s computerized sys-
tem to report the assay results. Three respondents from the
hospitals without assay facilities informed that they received
both the assay results and pharmacist’s dosing recommenda-
tion from the hospital that performed the drug assay for them.
All respondents in both groups reported that doctors in their
hospitals accepted the pharmacokinetic and dosing recommen-
dations made by the pharmacists.
Survey recipients were asked in which department the TDM
assay is done at their hospital. Of the 33 respondents, 23
(69.7%) reported that the drug assay was performed in the
TDM laboratory of the pharmacy department, while 10
(30.3%) said the assay was done in the biochemistry depart-
ment. Respondents reported using three different drug assays
for TDM. Out of 31 respondents who answered this question,
25 (80.6%) reported using ﬂuorescence polarization immuno-
assay technique (FPIA) and eight (25.8%) used enzyme-multi-
plied immunoassay technique (EMIT). High pressure liquid
chromatography (HPLC) technique was reported by one
respondent from a university hospital.
Twenty-four out of 31 (77.4%) respondents from hospitals
with their own drug assay facilities reported having quality
Table 1 Characteristics of hospitals that provide TDM service.
Hospital characteristics Hospitals with
TDM laboratory, N (%)
Hospitals without
TDM laboratory, N (%)
P valuea
Number of beds n= 34 n= 44 <0.001
<200 1 (2.9) 35 (79.5)
201–400 10 (29.4) 8 (18.2)
401–600 5 (14.7) 0 (0.0)
601–800 7 (20.6) 0 (0.0)
801–1000 7 (20.6) 0 (0.0)
>1000 4 (11.8) 1 (2.3)
Mean ± SD 681.0 ± 411.0 188.1 ± 377.9
Median 654.0 109.5
Range 114–2245 29–2600
Number of pharmacists n= 32 n= 43 <0.001
0 0 (0.0) 1 (2.3)
1 1 (3.1) 20 (46.5)
2–5 6 (18.8) 22 (51.2)
6–10 12 (37.5) 0 (0.0)
>10 13 (40.6) 0 (0.0)
Mean ± SD 10.3 ± 5.9 1.9 ± 1.2
Median 10.0 2.0
Range 1–30 0–5
Number of specialties n= 33 n= 36 <0.001
1 1 (3.0) 4 (11.1)
2–5 0 (0.0) 17 (47.2)
6–10 5 (15.2) 14 (38.9)
11–15 24 (72.7) 1 (2.8)
>15 3 (9.1) 0 (0.0)
Mean ± SD 12.4 ± 3.3 5.3 ± 2.8
Median 13.0 5.0
Range 1–17 1–11
‘‘n’’ indicates the number of respondents.
a Mann–Whitney test.
Table 2 Drugs monitored by TDM service.
Drugs monitored Hospitals with TDM
laboratory,
N (%)
Hospitals without
TDM laboratory,
N (%)
Aminoglycosides n= 33 n= 10
Gentamicin 32 (97.0) 7 (70.0)
Amikacin 24 (72.7) 0 (0.0)
Netilmicin 14 (42.4) 1 (10.0)
Antiepileptics n= 33 n= 10
Carbamazepine 33 (100) 8 (80.0)
Phenytoin 33 (100) 8 (80.0)
Sodium valproate 32 (97.0) 8 (80.0)
Phenobarbitone 25 (75.8) 5 (50.0)
Other drugs n= 34 n= 11
Paracetamol 30 (88.2) 5 (45.5)
Theophylline 29 (85.3) 3 (27.3)
Vancomycin 28 (82.4) 1 (9.1)
Digoxin 27 (79.4) 5 (45.5)
Cyclosporine 17 (50.0) 2 (18.2)
Aspirin 16 (47.0) 0 (0.0)
Methotrexate 6 (17.6) 0 (0.0)
Lithium 4 (11.8) 0 (0.0)
Tacrolimus 3 (8.8) 0 (0.0)
Opioids 1 (2.9) 0 (0.0)
‘‘n’’ indicates the number of respondents.
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dents participated in international QA programs. These inter-
national agencies included the International External Quality
Assessment (RIQAS), The Royal College of Pathologists of
Australia (RCPA) and United Kingdom National External
Quality Assessment Service (UKNEQAS). The rest of the
respondents reported that they participated in the hospital’s
internal QA programs and in those conducted by the Malay-
sian Ministry of Health.
4. Discussion
This study shows that TDMservice iswidely available in govern-
ment hospitals in Malaysia. Sixteen hospitals started their ser-
vice during the 1980s and the number of hospitals offering the
service has increased signiﬁcantly since then. Now, almost
two-thirds of government hospitals provide this service. Hospi-
tals that do not have the TDM service are generally those with
smaller number of hospital beds, pharmacists and medical
specialties. The ﬁndings from this study, to some extent, are sim-
ilar to those reported elsewhere (Murphy et al., 1991; Howard
et al., 1994; Morris, 1998). India started its TDM service by
the late 1980s and the service was widely available in the 1990s
to include more hospitals and centers (Gogtay et al., 2001).
Morris (1998) reported that not all hospitals in Australia
performed drug assay measurements in their own laboratories.
Drug assays for TDM are also performed by private laborato-
Table 3 Distribution of different sources of samples.
Source of samples Hospitals with
TDM laboratory,
N (%)
Hospitals without
TDM laboratory,
N (%)
Hospital departments n= 34 n= 10
Inpatients 34 (100.0) 10 (100.0)
Outpatients 33 (97.1) 6 (60.0)
Accident and
emergency department
11 (32.4) 0 (0.0)
Number of samples
received per month
n= 31 n= 10
<50 4 (12.9) 8 (80.0)
51–100 4 (12.9) 2 (20.0)
101–200 6 (19.4) 0 (0.0)
201–300 9 (29.0) 0 (0.0)
301–400 2 (6.45) 0 (0.0)
>400 6 (19.4) 0 (0.0)
Mean ± SD 286.7 ± 279.9 23.4 ± 30.1
Median 240.0 5.5
Range 8–1200 1–90
External sources n= 34 –
Other government hospitals 23 (67.6) –
Other government clinics 19 (55.9) –
Private hospitals 6 (17.6) –
Private laboratories 2 (5.9) –
Number of samples received
from external sources/month
n= 23 –
<50 12 (52.2) –
51–100 4 (17.4) –
101–150 6 (26.1) –
>150 1 (4.3) –
Mean ± SD 66.2 ± 63.6 –
Median 30.0 –
Range 1–240 –
‘‘n’’ indicates the number of respondents.
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Lam, 2002; Norris et al., 2010). Unlike in Australia, our survey
shows that hospitals that do not have their own drug assay
facilities rely on other hospitals to perform drug assays. Smal-
ler size hospitals rely on larger hospitals to provide the TDM
service where patient samples are sent to and assayed by the
latter. It is difﬁcult to determine exactly the reasons for estab-
lishing a TDM service in smaller size hospitals despite not hav-
ing drug assay facilities. It may be a combination of different
factors such as the availability of additional pharmacists, or
the demand from certain medical specialties in the hospital.
Half of the respondents in such hospitals reported that the
number of samples they received had increased over the years.
If this trend continues, the pharmacy departments may be
forced to allocate assay facilities at their own hospitals.
Almost all hospitals reported having only one pharmacist
to manage the TDM service. Most of the hospitals reported
providing the service only during weekdays. To provide a 24-
h service will require additional pharmacists working in three
different work-shifts. Therefore, the number of pharmacists in-
volved in TDM service has to be increased. Providing 24-h ser-
vice is common in developed countries (Koren et al., 1985;
Vinks et al., 1992). In USA, Murphy et al. (1996) reported that
TDM service was available for 24 h a day, 7 days a week in
11.9% of hospitals. In Europe, Thomson et al. (1998) reportedthat most of the TDM laboratories provided the service during
the weekdays while 73% of them offered a 24-h service for
emergency cases only and for speciﬁc types of drugs. Although
not being able to provide a 24-h service, some hospitals in this
country overcome this situation by providing an ‘‘on-call’’
TDM service. The ‘‘on-call’’ pharmacist is needed mainly for
emergency cases, either after normal working hours or during
weekends. The pharmacist does not have to be at the hospital
at all times but will be contactable by phone when his/her ser-
vice is required.
Larger hospitals are usually located in urban areas and ca-
ter for larger population size. They receive higher number of
TDM samples because many of them also received samples
from external sources like government clinics, private hospitals
and clinics. A similar trend has been reported by Cridland
(1994), that 70% of the TDM samples came from their hospi-
tal departments, while the rest came from 40 different institu-
tions. Because of the larger number of patients and specialties,
hospitals with their own drug assay facilities monitor more
drugs than those without drug assay facilities. The two most
common drugs monitored are antiepileptics and aminoglyco-
sides. Drugs like lithium, methotrexate, cyclosporine and
tacrolimus are infrequently monitored. These drugs are more
expensive or are used in more specialized settings and that
not all hospitals have these specialties.
Our survey shows that drug assays are performed either by
the department of pharmacy or by the department of biochem-
istry. The setting of the TDM laboratories varies between
different countries. Some reported that TDM services are per-
formed in the pharmacy departments (Murphy et al., 1991;
Vinks et al., 1992), while others reported that the analysis is per-
formed in the biochemistry department with the pharmacology
unit being responsible for providing the recommendations to
doctors (Pou and Campos, 1992). Reports from South Africa,
India and Turkey showed that the TDM laboratory is part of
the pharmacology department ( Cridland, 1994; Yamantu¨rk
et al., 2000; Gogtay et al., 2001). Some institutions in Australia
have both practices, that the easier assays were performed in
the clinical biochemistry or chemical pathology departments,
while the more complex assays like cyclosporine were per-
formed in the clinical pharmacology department (Morris,
1998).
Only two types of immunoassays are used by our hospitals,
with FPIA being the most common. Similarly, FPIA seems to
be the most common analytical method used in other countries
(Cridland, 1994; Thomson et al., 1998; Yamantu¨rk et al., 2000;
Morris and Lam, 2002). The high usage of this technique by
most hospitals probably reﬂects the ease of use of the system,
which requires minimal maintenance and personnel training.
However, the choice of drug immunoassays has been under
scrutiny. Interference from drug metabolite and other endoge-
nous substances in patient samples has been highlighted with
drug assays for cyclosporine and digoxin (Morris, 2000; Rog-
ers et al., 2010). Despite recommendations from the literature
(Morris et al., 2002), a large percentage of laboratories still em-
ploy poor performing immunoassays (Norris et al., 2010). We
did not determine how the choice of drug assay was made by
each hospital, although cost is probably a major determinant.
As with other developing countries, the main drawback of
immunoassay is the high cost of reagents. In this survey we
did not evaluate the cost per test. In India, the cost has been
reported to be approximately £3–£4 per test (Gogtay et al.,
A survey of therapeutic drug monitoring services in Malaysia 232001). Indonesia has not yet started its TDM service and the
high cost of drug assays poses a major barrier toward imple-
menting a TDM service in that country (Setiabudy, 2011). Like
earlier reports, we found that chromatographic technique was
not commonly used (Gogtay et al., 2001; Morris and Lam,
2002). This technique needs highly skilled personnel and long
turnaround time to perform the assay. It is unlikely that this
methodology is to be widely used in this country for the pur-
pose of TDM.
The majority of respondents said they participated in qual-
ity assurance programs. The nature of these programs varies
between different hospitals. One-third of those hospitals in-
volved in the QA programs participate in international QA
program schemes while the rest are carried out locally. Morris
(1994) reported that 30% of CSA TDM laboratories in Aus-
tralia participated in an external QA program and recent data
showed an increase in the number of hospitals (71%) regis-
tered in an international testing scheme (Morris and Lam,
2002). Pedersen et al. (2000) reported that 29% of the hospitals
in USA had a regular program to evaluate the quality of the
clinical monitoring service provided. Participation in interna-
tional QA programs helps to maintain the quality of TDM ser-
vice, which is required for future accreditations.
Based on the ﬁndings from this survey, the following recom-
mendations should be considered: (1) an increasing demand for
TDM service will lead to an increase in hospital costs. Within
the same hospital, policy makers must decide whether it is more
economically favorable to consolidate resources in the phar-
macy department and biochemistry department (Shenﬁeld,
2001). (2) Commercially available assays are costly. The choice
of assay methodology should not only take into account its cost
but also assay cross-reactivity and performance. For example,
hospitals that offer TDM of cyclosporine may beneﬁt from rec-
ommendations in the guideline by Morris et al. (2002). At the
same time, laboratories that perform drug assays should be
encouraged to participate in quality assurance programs, and
(3) appropriate use of TDM resources must be enforced. The
presence of TDM guidelines alone does not guarantee compli-
ance (Leong et al., 2006). Instead, TDM pharmacists should
consider increasing their involvement in clinical activities as
well. The presence of the pharmacist during clinical rounds
has been shown to reduce inappropriateness and monitoring
costs (Kraus et al., 1991; Ratanajamit et al., 2009).
5. Conclusions
TDM service is widely available in government hospitals in
Malaysia. Although drug assay facilities are not always avail-
able in the pharmacy departments, pharmacokinetic consulta-
tions are performed by pharmacists. Thus, they have the
responsibilities to ensure the optimum use of TDM to guide
drug therapy in patients.
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